K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement

International Journal of Cancer

Volumn 93, Issue 6, 2001, Pages 848-854

  Jurianz, Katrin ^a   Ziegler, Stefanie ^a   Donin, Natalie ^b   Reiter, Yoram ^a   Fishelson, Zvi ^a   Kirschfink, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Complement; Human; Tumor immunity

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; PROTEIN KINASE C INHIBITOR;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOLYSIS; ERYTHROLEUKEMIA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; SENSITIZATION; TUMOR CELL LINE;

ALPHA-AMYLASE; ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; CELL MEMBRANE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; FLOW CYTOMETRY; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MEMBRANE GLYCOPROTEINS; NAPHTHALENES; NEUTROPHILS; PLANT PROTEINS; PROTEIN KINASE C; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; TRYPSIN INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035885261     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1406     Document Type: Article

References (48)

1. Protection of thyroid cancer cells by complement-regulatory factors
2. Persistent complement activation on tumor cells in breast cancer
3. Experimental tumoricidal effects of monoclonal antibody against solid breast tumors
4. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity
5. Immune evasion of tumor cells using membrane-bound complement regulatory proteins
6. C3-cleaving membrane proteinase. A new complement regulatory protein of human melanoma cells
7. A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma
8. Phosphorylation of the complement component C9 by an ecto-protein kinase of human leukemic cells
9. The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium
10. 2+
11. Protein phosphorylation as a mechanism of resistance against complement damage
12. Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination
13. Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C
14. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement
15. Humoral immune killing of nucleated cells: Mechanisms of complement-mediated attack and target cell defense
16. Complement membrane attack complexes induce in human leukemic cells rapid expression of large proteins (L-CIP)
17. Time-resolved fluorometric assay for natural killer activity using target cells labeled with a fluorescence enhancing ligand
18. Characterization of three monoclonal antibodies to membrane co-factor protein (MCP) of the complement system and quantification of MCP by radioassay
19. Human skeletal myoblasts spontaneously activate allogenic complement but are resistant to killing
20. Crystalline soybean trypsin inhibitor
21. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma
22. Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells
23. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma
24. Neutralization of complement regulatory proteins augments lysis of mammary carcinoma cells targeted with rhuMAb anti-HER2
25. Complement, a biologic effector mechanism for tumor cell killing
26. Complement resistance of tumor cells: Basal and induced mechanisms
27. Membrane cofactor protein (CD46) protect cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis
28. Structure and function of decay-accelerating factor CD55
29. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalyzed insertion of C9 into lipid bilayers
30. Frequent expression of complement resistance factors CD46, CD55, and CD55 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A
31. Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium
32. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-cytotoxicity
33. Complement-regulatory proteins on ovarian malignancies
34. Levels of complement regulator proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human hematological malignancies
35. Complement activation by malignant B cells from patients with chronic lymphocytic leukemia (CLL)
36. Expression of messenger RNAs for complement inhibitors in human tissues and tumors
37. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is downregulated during cell differentiation
38. Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies
39. Regulation of CD59 expression on K562 cells: Effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack
40. Analysis of the gene that encodes the complement regulatory protein, membrane inhibitor of reactive lysis (CD59). Identification of an alternatively spliced exon and characterization of the transcriptional regulatory regions of the promoter
41. Cytokines modulate expression of cell-membrane complement inhibitory proteins in human lung cancer cell lines
42. Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C
43. The influence of tumour necrosis factor-alpha, interleukin-1 beta and interferon-gamma on the expression and function of the complement regulatory protein CD59 on the human colonic adenocarcinoma cell line HT29
44. Characterization of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line
45. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity
46. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C' 1r subcomponent of the first component of complement by serum C' 1 esterase inhibitor
47. Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells